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GestationAβ-hemolytic Enterococcus faecalis strain agglutinating Lanceﬁeld groupA, B, C, D, F, andG antiserawas observed
froma rectovaginal swab, in the context of antenatal screening for Streptococcus agalactiae (group B Streptococcus
[GBS]). This is the ﬁrst multi-Lanceﬁeld antisera-agglutinating isolate of this species, and it raised particular con-
cern, as it may mimic GBS, leading to false reporting and useless receipt of intrapartum antibiotics.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Short communication
Streptococcus agalactiae (group B Streptococcus [GBS]) may inhabit
the human gut fromwhich, in 30% of cases, it colonizes the female gen-
ital tract (CDC, 2010; Creti et al., 2013). Pregnant women can be, there-
fore, symptomatic or silent GBS carriers and then potentially transmit
the microorganism to the newborn at the time of delivery (CDC, 2010;
Creti et al., 2013). In the absence of an intrapartumantibiotic prophylax-
is (IAP), which is based on intravenous penicillin or ampicillin, 1–2% of
neonates may, therefore, develop an early GBS infection (bacteremia,
pneumonia, and meningitis). According to the CDC (2010), then,
antepartum screening should rely on rectovaginal cultures performed
at 35th–37th week of gestation and has the purpose of timely adminis-
tering IAP, when labor begins or amniotic membranes rupture occurs
(CDC, 2010; Creti et al., 2013).
GBS is mostly β-hemolytic, less commonly nonhemolytic (γ-hemolytic);
however, although rare, α-hemolytic strains are described (Teixeira
et al., 2003). A pregnant woman underwent GBS antepartum screening
according to CDC (2010) guidelines at the Spirito Santo Hospital of
Pescara, Italy, and on trypticase soy agar (Lioﬁlchem®, Roseto degli
Abruzzi, Italy), β-hemolytic colonies grew easily overnight, after 24-hInc. This is an open access article upreincubation in selective enrichment broth (Todd Hewitt broth;
Lioﬁlchem®). The isolate showed agglutination with Lanceﬁeld group
B antiserum (Lioﬁlchem® Strepto B latex kit), but unexpectedly, it
was CAMP test negative and produced Enterococcus faecalis–like colo-
nies (violet colored) on the Lioﬁlchem® Chromatic StrepB (Fig. 1). Ac-
cordingly, identiﬁcation as E. faecalis was obtained by using the Vitek2
GP card (bioMérieux, Marci l'Etoile, France) and the API 20 Strep
(bioMérieux). As, however, a multi-Lanceﬁeld antigen-agglutinating En-
terococcus durans strain from a pregnant womanwas recently described
(Savini et al., 2014), antisera from different manufacturers (Lioﬁlchem®
Strep-Check and bioMérieux Slidex Strepto Plus kits) were used and re-
vealed, surprisingly, concomitant A, B, C, D, F, and G agglutination (Fig. 2).
The identiﬁcation was then conﬁrmed by means of further method-
ologies. The isolate was analyzed through commercial in situ hybridiza-
tion (Quick-FISH®; AdvanDx, Woburn, MA, USA), using an in-house
protocol; based on the latter, a single colony grown overnight on
sheep blood agar was transferred into the center of the sample area of
a QuickFISH® slide (previously placed on a workstation heated at
55 °C) and mixed gently with a drop of saline. Subsequent smear ﬁxa-
tion, hybridization, and slide evaluation were performed following the
manufacturer's procedure for blood cultures. The colony showed a
green ﬂuorescence, which is characteristic for E. faecalis (positive and
negative controls are present on the same QuickFISH® slide).
Furthermore, the isolate was tested with the Xpert GBS (Cepheid,
Sunnyvale, CA, USA), based on a modiﬁed protocol. A single colonynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Strain R48 (Ef122) (see text) on the Lioﬁlchem® Chromatic StrepB.
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tridge that was ﬁnally placed into the Xpert instrument; as a result, no
ampliﬁcation for the GBS target was obtained (as positive and negative
controls, S. agalactiae ATCC 13813 and E. faecalis ATCC 29212 were
used, respectively).
Finally, the isolate was conﬁrmed to be E. faecalis by a multiplex
polymerase chain reaction (PCR) assay for the species-speciﬁc targets
DdlE. faecalis and ddlE. faecium genes encoding D-Ala:D-Ala ligases
and related glycopeptide resistance enzyme, using primers E1 (5′-
ATCAAGTACAGTTAGTCTT-3′) and E2 (5′-ACGATTCAAAGCTAACTG-3′)
for E. faecalis and F1 (5′-GCAAGGCTTCTTAGAGA-3′) and F2 (5′-
CATCGTGTAAGCTAACTTC-3′) for E. faecium, respectively (Dutka-Malen
et al., 1995). Additionally, further agreement on identiﬁcation to the spe-
cies level was obtained by 16S rRNA gene sequencing using universal
primers as previously described (Eden et al., 1991); the ampliﬁcation
product was analyzed using CLC DNAWorkbench 5.5 and BLAST analysis
(NCBI; http://blast.ncbi.nlm.nih.gov/Blast.cgi) revealing a 100% homology
of the partial sequence of 705 bp with E. faecalis ATCC 19433 (accession
number DQ411814.1).
Thewomanwas, therefore, conclusively considered tobeGBSnegative.
The studied strain showed susceptibility to beta-lactams and glyco-
peptides according to the European Committee for Antibiotic Suscepti-
bility Testing 2014 criteria (for enterococci). Vancomycin and
teicoplanin MICs were evaluated by using the broth microdilution
method (Trek Diagnostic Systems; Thermo Fisher Scientiﬁc, Oakwood
Village, OH, USA), based on the manufacturer's instructions, as well asFig. 2. Strain R48 (Ef122) (see text) Lanceﬁeld antisera agglutination (letters indicate re-
spective Lanceﬁeld antigen group).through the Lioﬁlchem®MIC Test Strips; susceptibility to glycopeptides
was further conﬁrmed by the absence of van genes as determined by the
above-cited multiplex PCR (Dutka-Malen et al., 1995).
The organism was stored in the internal collection of the Microbiol-
ogy and Virology Laboratory, Spirito Santo Hospital of Pescara, Italy, and
of the Istituto Zooproﬁlattico Sperimentale delle Regioni Lazio e Tosca-
na, Rome, Italy, under the accession numbers R48 (Ef122) and
14018081–8, respectively.
Enterococci may mimic S. agalactiae when they show a clearly β-
hemolytic phenotype (e.g., Enterococcus gallinarum, E. faecalis, and
E. durans); nevertheless, with the exception of the abovementioned
E. durans strain (Savini et al., 2014), GBS-like isolatesmay be easily recog-
nized as they cannot agglutinate group B antiserum. Particularly,
E. faecalis has been described to show D or G agglutination only (Harvey
and McIllmurray, 1984; Hopfer et al., 1985; Savini et al., 2012); thus far,
so to the best of our knowledge, this report depicts the ﬁrst multi-
Lanceﬁeld antigen-agglutinating, GBS-like E. faecalis strain.
This report then emphasizes that identiﬁcation of group B–
agglutinating isolates as S. agalactiae, based on latex assays only, may
be responsible for false reports of GBS carriage, then for useless IAP re-
ceipt. Prevalence of group B–agglutinating enterococci is unknown, as
thus far, only the abovementioned report dealing with an E. durans
strain has been published (Savini et al., 2014). Therefore, it is currently
debatablewhether and how frequently suchunusual isolates aremistak-
en for GBS in the clinical practice. Allβ-hemolytic, group B–agglutinating
isolates must be carefully and thoroughly investigated, therefore, before
being labeled as GBS, with the purpose to avoid falsely positive
antepartum reports and to better understand the epidemiology and
spread of GBS-like enterococci. Particularly, presumptive identiﬁcation
based on group B agglutination should andmight be conﬁrmed through
diverse and different assays, including currently available phenotype-
and genotype-based methods such as CAMP test, chromogenic media,
Vitek2, the API system, FISH methodology, Xpert technology, end-point
PCR, and 16S rRNA gene sequencing, which may allow to timely and re-
liably diagnose or exclude GBS carriage and prevent useless IAP.
Nucleotide sequence accession number. The strain R48 (Ef122)
16S rRNAgene sequencewas deposited in GenBank under the accession
number KJ789396.
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